Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...
China: A prospective multicentre cohort study from China suggests that telitacicept, when used alongside standard of care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback